IQVIA Hlds (IQV) Stock Forecast & Price Target

IQVIA Holdings is viewed positively because its Commercial Solutions business is entering a favorable demand inflection, with 20 novel drug approvals in 3Q26, 43 approvals YTD in 2026, and the highest quarterly total tracked since 2021, which should feed commercialization spend over the next few years. Its R&DS franchise also shows strengthening fundamentals, highlighted by the highest net new bookings since 2022, record NTM backlog revenue of $9.2B, and 7.5% y/y backlog growth, while management points to improving large-pharma and biotech demand. Underlying execution remains solid, with margin expansion already occurring ahead of schedule and supported by high book-to-bill, strong data and analytics assets, and an established position across clinical research and technology services.

IQVIA Holdings is viewed negatively because its core clinical research franchise is vulnerable to execution risk: slower patient enrollment, site selection problems, and talent shortages could delay or cancel trials, damaging its reputation and revenue generation across the 3,000 studies it conducts globally. The company’s data advantage is also a liability, since it manages over 1.2 billion patient records, about 64 petabytes of proprietary data, and roughly 120 billion healthcare records annually, making cybersecurity or data-service disruptions especially consequential. More broadly, funding uncertainty, government delays at agencies like the FDA, AI disruption concerns, FX variance, slower pharma spending, and debt-service pressures all threaten growth, margins, and balance-sheet flexibility.